Evidence map›Paper›PMID 42487136›Full record

ArticleActa neuropathologica communications2026

Methylation profiling and alternative classification approaches in a glioma-enriched FFPE stereotaxic biopsy cohort.

Katharina Johanna Weber, Jürgen Hench, Markus Zumpt, Thomas Eska, Moritz Armbrust, Pia Susann Zeiner, Tabea Isabelle Hartung, Viktoria Ruf, Eike Steidl, Mareike Dettki and 8 more

Abstract read
In one paragraph

Article in Acta neuropathologica communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Katharina Johanna WeberGoethe University Frankfurt, University Hospital, Neurological Institute (Edinger Institute), Heinrich-Hoffmann-Straße 7, 60528, Frankfurt am Main, Germany. K.Weber@med.uni-frankfurt.de.ORCID 0000-0001-9395-8944
Jürgen HenchDivision of Neuropathology, Institute of Pathology, Basel University Hospital, Schönbeinstrasse 40, 4031, Basel, Switzerland.
Markus ZumptGoethe University Frankfurt, University Hospital, Neurological Institute (Edinger Institute), Heinrich-Hoffmann-Straße 7, 60528, Frankfurt am Main, Germany.
Thomas EskaLudwig Maximilians University Munich, University Hospital, Center for Neuropathology and Prion Research, Faculty of Medicine, Feodor-Lynen-Straße 23, 81377, Munich, Germany.
Moritz ArmbrustGoethe University Frankfurt, University Hospital, Neurological Institute (Edinger Institute), Heinrich-Hoffmann-Straße 7, 60528, Frankfurt am Main, Germany.
Pia Susann ZeinerGerman Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Partner Site Frankfurt, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
Tabea Isabelle HartungUniversity Hospital Hamburg-Eppendorf, Martinistraße 52, 20251, Hamburg, Germany.
Viktoria RufLudwig Maximilians University Munich, University Hospital, Center for Neuropathology and Prion Research, Faculty of Medicine, Feodor-Lynen-Straße 23, 81377, Munich, Germany.
Eike SteidlGoethe University Frankfurt, University Hospital, Institute of Neuroradiology, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.
Mareike DettkiGoethe University Frankfurt, University Hospital, Dr. Senckenberg Institute of Neurooncology, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.
Tim FentonSchool of Cancer Sciences, University of Southampton, University Road, Southampton, SO17 1BJ, UK.
Joachim Peter SteinbachGerman Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Partner Site Frankfurt, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
Marcus CzabankaGoethe University Frankfurt, University Hospital, Department of Neurosurgery, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.
David CapperCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neuropathology, Charitéplatz 1, 10117, Berlin, Germany.
Stephan FrankDivision of Neuropathology, Institute of Pathology, Basel University Hospital, Schönbeinstrasse 40, 4031, Basel, Switzerland.
Karl-Heinz PlateGoethe University Frankfurt, University Hospital, Neurological Institute (Edinger Institute), Heinrich-Hoffmann-Straße 7, 60528, Frankfurt am Main, Germany.
Marie-Thérèse ForsterGoethe University Frankfurt, University Hospital, Department of Neurosurgery, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.
Patrick Nikolaus HarterLudwig Maximilians University Munich, University Hospital, Center for Neuropathology and Prion Research, Faculty of Medicine, Feodor-Lynen-Straße 23, 81377, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DNA methylation profiling of CNS tumors supports and refines histological diagnoses. Tumor DNA methylation signatures allow for an alignment with reference methylation classes and copy number profiling required for molecular grading. Overall, and especially in cases with limited tissue like in stereotaxic (STX) biopsies, there is a need for informed triage to most promising analysis techniques. Here, we investigated the diagnostic potential and accuracy of DNA methylation profiling and molecular grading in STX samples. FFPE samples of 237 patients were subjected to DNA methylation analysis including the Heidelberg (v11b4), Bethesda (v2) and EpiDiP brain tumor classifiers, copy number profiling and tumor deconvolution using MethylCIBERSORT. 90.5% of samples (n = 232) were allocated DNA methylation classes, with 61.6% reaching Heidelberg classifier scores of > 0.84. Indicatory copy number variations (CNVs) were detectable in 96.9% of cases. Recursive partitioning supported by a resampling-based validation with repeated random subsampling pointed towards brain tumor classifier dependent minimum analyte inputs to reach robust calibrated scores for DNA methylation class allocation. Successful integrative diagnostics furthermore depended on pre-classifier H&E diagnoses with 96.2% of H&E malignant diffuse gliomas, 91.5% of H&E diffuse gliomas but only 60% of H&E circumscribed gliomas classifiable using the Heidelberg brain tumor classifier. When the alternative classifiers EpiDiP and Bethesda were used, higher DNA input amounts ameliorated the classification robustness. Nevertheless, diagnostics of high-grade gliomas in midline location and lower-grade glial/glioneuronal tumors posed a challenge. Our findings demonstrate the broad applicability of DNA methylation profiling and molecular grading to small brain tumor specimens under the caveat of certain tumors and locations potentially benefiting from additional molecular as well as computational approaches to increase methylation signals relevant for classification in the future.

Indexed as

Brain NeoplasmsDNA MethylationGliomaAdultAgedBiopsyCohort StudiesDNA Copy Number VariationsFemaleHumansMaleMiddle AgedNeoplasm GradingStereotaxic TechniquesYoung AdultBethesda brain tumor classifierEpiDiPGlioblastoma, IDH-wildtypeHeidelberg brain tumor classifierStereotaxic biopsyTumor deconvolution

Identifiers

PMID42487136
PMCPMC13393821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.